The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hepatitis C Virus (HCV) Antiviral Market Research Report 2025
Synopsis
Hepatitis C is a contagious liver disease caused due to hepatitis C virus. Hepatitis C damages and infects the liver. Hepatitis C is spread as the infected blood comes in contact with non-infected blood. Ranging in severity hepatitis C can cause acute and chronic hepatitis infection. Chronic hepatitis C is diagnosed by liver biopsy and blood tests. According to World Health Organization (WHO), globally 130 million to 150 million people are suffering from chronic hepatitis C. Hepatitis C is treated with antiviral drugs to inhibit the growth of virus and prevent liver damage. According to World Health Organization (WHO), 50% to 90% of people suffering from hepatitis C are treated with antiviral treatment.
The global Hepatitis C Virus (HCV) Antiviral market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis C Virus (HCV) Antiviral, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis C Virus (HCV) Antiviral.
Report Scope
The Hepatitis C Virus (HCV) Antiviral market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis C Virus (HCV) Antiviral market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis C Virus (HCV) Antiviral companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche Diagnostics
Abbott
Siemens
Qiagen
bioMérieux
Bio-Rad Laboratories
Meridian Bioscience
Vista Diagnostics
Biogate Laboratories
J.Mitra & Co. Ltd
Siemens Medical
General Biologicals
Segment by Type
HCV Antibody
HCV Viral Load
HCV Genotyping
Segment by Application
Diagnostic Centers
Hospitals
Home Use
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis C Virus (HCV) Antiviral companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hepatitis C is a contagious liver disease caused due to hepatitis C virus. Hepatitis C damages and infects the liver. Hepatitis C is spread as the infected blood comes in contact with non-infected blood. Ranging in severity hepatitis C can cause acute and chronic hepatitis infection. Chronic hepatitis C is diagnosed by liver biopsy and blood tests. According to World Health Organization (WHO), globally 130 million to 150 million people are suffering from chronic hepatitis C. Hepatitis C is treated with antiviral drugs to inhibit the growth of virus and prevent liver damage. According to World Health Organization (WHO), 50% to 90% of people suffering from hepatitis C are treated with antiviral treatment.
The global Hepatitis C Virus (HCV) Antiviral market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis C Virus (HCV) Antiviral, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis C Virus (HCV) Antiviral.
Report Scope
The Hepatitis C Virus (HCV) Antiviral market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis C Virus (HCV) Antiviral market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis C Virus (HCV) Antiviral companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche Diagnostics
Abbott
Siemens
Qiagen
bioMérieux
Bio-Rad Laboratories
Meridian Bioscience
Vista Diagnostics
Biogate Laboratories
J.Mitra & Co. Ltd
Siemens Medical
General Biologicals
Segment by Type
HCV Antibody
HCV Viral Load
HCV Genotyping
Segment by Application
Diagnostic Centers
Hospitals
Home Use
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis C Virus (HCV) Antiviral companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatitis C Virus (HCV) Antiviral Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 HCV Antibody
1.2.3 HCV Viral Load
1.2.4 HCV Genotyping
1.3 Market by Application
1.3.1 Global Hepatitis C Virus (HCV) Antiviral Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Diagnostic Centers
1.3.3 Hospitals
1.3.4 Home Use
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatitis C Virus (HCV) Antiviral Market Perspective (2019-2030)
2.2 Hepatitis C Virus (HCV) Antiviral Growth Trends by Region
2.2.1 Global Hepatitis C Virus (HCV) Antiviral Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hepatitis C Virus (HCV) Antiviral Historic Market Size by Region (2019-2024)
2.2.3 Hepatitis C Virus (HCV) Antiviral Forecasted Market Size by Region (2025-2030)
2.3 Hepatitis C Virus (HCV) Antiviral Market Dynamics
2.3.1 Hepatitis C Virus (HCV) Antiviral Industry Trends
2.3.2 Hepatitis C Virus (HCV) Antiviral Market Drivers
2.3.3 Hepatitis C Virus (HCV) Antiviral Market Challenges
2.3.4 Hepatitis C Virus (HCV) Antiviral Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatitis C Virus (HCV) Antiviral Players by Revenue
3.1.1 Global Top Hepatitis C Virus (HCV) Antiviral Players by Revenue (2019-2024)
3.1.2 Global Hepatitis C Virus (HCV) Antiviral Revenue Market Share by Players (2019-2024)
3.2 Global Hepatitis C Virus (HCV) Antiviral Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatitis C Virus (HCV) Antiviral Revenue
3.4 Global Hepatitis C Virus (HCV) Antiviral Market Concentration Ratio
3.4.1 Global Hepatitis C Virus (HCV) Antiviral Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatitis C Virus (HCV) Antiviral Revenue in 2023
3.5 Hepatitis C Virus (HCV) Antiviral Key Players Head office and Area Served
3.6 Key Players Hepatitis C Virus (HCV) Antiviral Product Solution and Service
3.7 Date of Enter into Hepatitis C Virus (HCV) Antiviral Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatitis C Virus (HCV) Antiviral Breakdown Data by Type
4.1 Global Hepatitis C Virus (HCV) Antiviral Historic Market Size by Type (2019-2024)
4.2 Global Hepatitis C Virus (HCV) Antiviral Forecasted Market Size by Type (2025-2030)
5 Hepatitis C Virus (HCV) Antiviral Breakdown Data by Application
5.1 Global Hepatitis C Virus (HCV) Antiviral Historic Market Size by Application (2019-2024)
5.2 Global Hepatitis C Virus (HCV) Antiviral Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hepatitis C Virus (HCV) Antiviral Market Size (2019-2030)
6.2 North America Hepatitis C Virus (HCV) Antiviral Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hepatitis C Virus (HCV) Antiviral Market Size by Country (2019-2024)
6.4 North America Hepatitis C Virus (HCV) Antiviral Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatitis C Virus (HCV) Antiviral Market Size (2019-2030)
7.2 Europe Hepatitis C Virus (HCV) Antiviral Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hepatitis C Virus (HCV) Antiviral Market Size by Country (2019-2024)
7.4 Europe Hepatitis C Virus (HCV) Antiviral Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Market Size (2019-2030)
8.2 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Market Size by Region (2019-2024)
8.4 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hepatitis C Virus (HCV) Antiviral Market Size (2019-2030)
9.2 Latin America Hepatitis C Virus (HCV) Antiviral Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hepatitis C Virus (HCV) Antiviral Market Size by Country (2019-2024)
9.4 Latin America Hepatitis C Virus (HCV) Antiviral Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis C Virus (HCV) Antiviral Market Size (2019-2030)
10.2 Middle East & Africa Hepatitis C Virus (HCV) Antiviral Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hepatitis C Virus (HCV) Antiviral Market Size by Country (2019-2024)
10.4 Middle East & Africa Hepatitis C Virus (HCV) Antiviral Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche Diagnostics
11.1.1 Roche Diagnostics Company Detail
11.1.2 Roche Diagnostics Business Overview
11.1.3 Roche Diagnostics Hepatitis C Virus (HCV) Antiviral Introduction
11.1.4 Roche Diagnostics Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.1.5 Roche Diagnostics Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Hepatitis C Virus (HCV) Antiviral Introduction
11.2.4 Abbott Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.2.5 Abbott Recent Development
11.3 Siemens
11.3.1 Siemens Company Detail
11.3.2 Siemens Business Overview
11.3.3 Siemens Hepatitis C Virus (HCV) Antiviral Introduction
11.3.4 Siemens Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.3.5 Siemens Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Detail
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Hepatitis C Virus (HCV) Antiviral Introduction
11.4.4 Qiagen Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.4.5 Qiagen Recent Development
11.5 bioMérieux
11.5.1 bioMérieux Company Detail
11.5.2 bioMérieux Business Overview
11.5.3 bioMérieux Hepatitis C Virus (HCV) Antiviral Introduction
11.5.4 bioMérieux Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.5.5 bioMérieux Recent Development
11.6 Bio-Rad Laboratories
11.6.1 Bio-Rad Laboratories Company Detail
11.6.2 Bio-Rad Laboratories Business Overview
11.6.3 Bio-Rad Laboratories Hepatitis C Virus (HCV) Antiviral Introduction
11.6.4 Bio-Rad Laboratories Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.6.5 Bio-Rad Laboratories Recent Development
11.7 Meridian Bioscience
11.7.1 Meridian Bioscience Company Detail
11.7.2 Meridian Bioscience Business Overview
11.7.3 Meridian Bioscience Hepatitis C Virus (HCV) Antiviral Introduction
11.7.4 Meridian Bioscience Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.7.5 Meridian Bioscience Recent Development
11.8 Vista Diagnostics
11.8.1 Vista Diagnostics Company Detail
11.8.2 Vista Diagnostics Business Overview
11.8.3 Vista Diagnostics Hepatitis C Virus (HCV) Antiviral Introduction
11.8.4 Vista Diagnostics Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.8.5 Vista Diagnostics Recent Development
11.9 Biogate Laboratories
11.9.1 Biogate Laboratories Company Detail
11.9.2 Biogate Laboratories Business Overview
11.9.3 Biogate Laboratories Hepatitis C Virus (HCV) Antiviral Introduction
11.9.4 Biogate Laboratories Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.9.5 Biogate Laboratories Recent Development
11.10 J.Mitra & Co. Ltd
11.10.1 J.Mitra & Co. Ltd Company Detail
11.10.2 J.Mitra & Co. Ltd Business Overview
11.10.3 J.Mitra & Co. Ltd Hepatitis C Virus (HCV) Antiviral Introduction
11.10.4 J.Mitra & Co. Ltd Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.10.5 J.Mitra & Co. Ltd Recent Development
11.11 Siemens Medical
11.11.1 Siemens Medical Company Detail
11.11.2 Siemens Medical Business Overview
11.11.3 Siemens Medical Hepatitis C Virus (HCV) Antiviral Introduction
11.11.4 Siemens Medical Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.11.5 Siemens Medical Recent Development
11.12 General Biologicals
11.12.1 General Biologicals Company Detail
11.12.2 General Biologicals Business Overview
11.12.3 General Biologicals Hepatitis C Virus (HCV) Antiviral Introduction
11.12.4 General Biologicals Revenue in Hepatitis C Virus (HCV) Antiviral Business (2019-2024)
11.12.5 General Biologicals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
